Innocan Pharma Corp. buy Frank04
Start price
18.09.23
/
70%
€0.26
Target price
18.09.24
€1.00
Performance (%)
-27.01%
Price
02.05.24
€0.19
Summary
This prediction is currently active. The price of Innocan Pharma Corp. has decreased since the start of the prediction. Compared to the start price this results in a performance of -27.01%. This prediction currently runs until 18.09.24. The prediction end date can be changed by Frank04 at any time. Frank04 has 70% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Innocan Pharma Corp. | - | - |
| iShares Core DAX® | 0.000% | -2.064% |
| iShares Nasdaq 100 | 0.626% | -2.884% |
| iShares Nikkei 225® | 1.568% | -5.892% |
| iShares S&P 500 | 0.334% | -2.281% |
According to Frank04 what are the pros and cons of Innocan Pharma Corp. for the foreseeable future?
Pros
Differentiated customer and product portfolio
Leading role in innovation
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Good rating
Very capable Management
Some uniques
Cons
Higher risks for its business
Comments by Frank04 for this prediction
In the thread Innocan Pharma Corp. diskutieren
Buy Innocan Pharma Corp.